LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -48.39% | -105.90% | 1,235.69% | 24.95% | -81.56% |
| Total Depreciation and Amortization | 24.51% | 20.95% | 30.75% | 2.61% | 2.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.63% | 115.46% | -968.69% | -39.11% | 66.60% |
| Change in Net Operating Assets | 194.98% | -45.12% | 40.19% | 25.98% | 71.00% |
| Cash from Operations | 207.26% | 8.33% | 606.11% | 18.41% | 94.48% |
| Capital Expenditure | -12.13% | -137.10% | 187.17% | -29.16% | -68.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -3,536.82% | 98.57% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -40.08% | 81.14% | -1,118.06% | 17.52% | -37.03% |
| Cash from Investing | -26.07% | 63.01% | -49.48% | 56.83% | -362.94% |
| Total Debt Issued | 49.50% | -39.66% | 255.50% | 300.68% | -65.18% |
| Total Debt Repaid | -16.13% | 83.52% | -306.69% | 18.07% | -165.45% |
| Issuance of Common Stock | -- | -- | -100.00% | -81.84% | 166.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -24.06% | 9.81% | -31.51% | 54.67% | -262.86% |
| Cash from Financing | 68.24% | 41.99% | 30.65% | -62.92% | 41.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.75% | 1,626.41% | 202.95% | -138.93% | 874.01% |